Sinopharm stock sits 7.82 percent below HKD 16.95 target from 14 analysts

Published on 10/17/2026 at 19:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Six-month revenue was RMB 282.80 billion on June 30, 2026. Sinopharm stock closed at HKD 15.72 on October 16, 2026, up 0.45 percent on HKEX.

Analyst view and reporting date

On October 14, 2026, 14 ratings put the average Sinopharm target at HKD 16.95, 7.82 percent above the latest price.
For the six months ended June 30, 2026, revenue reached RMB 282.80 billion, down 1.13 percent year over year.
Sinopharm stock closed at HKD 15.72 on October 16, 2026 at 4:08 p.m. HKST, up 0.45 percent on HKEX.
Sinopharm is scheduled to report second-quarter 2026 earnings on November 2, 2026.

Sinopharm, CNE100000FN7, Illustration mit AI erstellt.

Sinopharm stock sits 7.82 percent below the HKD 16.95 average target from 14 analyst ratings. According to Barron's on October 14, 2026, the average target was HKD 16.95. Sinopharm stock closed at HKD 15.72 on HKEX on October 16, 2026 at 4:08 p.m. HKST, up 0.45 percent on the day.

First-half revenue fell 1.13 percent

Sinopharm reported revenue of RMB 282.80 billion for the six months ended June 30, 2026, down 1.13 percent from the year-earlier period. Net profit reached RMB 5.18 billion, a decline of 2.95 percent, while net profit attributable to shareholders was RMB 3.40 billion, down 1.79 percent. These figures come from the 2026 interim report carried by Futunn on September 23, 2026.

Range and year-to-date performance

The HKEX stock traded within a 52-week range of HKD 14.55 to HKD 22.34 on October 16, 2026. The closing price stood 8.04 percent above the low and 29.63 percent below the high. The year-to-date performance was minus 20.06 percent. Trading volume was 5.82 million shares, against an average of 4.90 million.

Valuation and November earnings date

Sinopharm had a market capitalization of HKD 49.1 billion and a trailing P/E ratio of 5.94 on October 16, 2026. Barron's lists November 2, 2026 as the reporting date for second-quarter 2026 earnings. The date gives investors a defined calendar point for reassessing the revenue decline and the target gap.

Comparison with peers

Sinopharm (HKEX, HKD): plus 0.45 percent, P/E 5.94, market capitalization HKD 49.1 billion
Sino Biopharmaceutical (HKEX, HKD): minus 0.38 percent, P/E 33.78, market capitalization HKD 93.5 billion
Anhui Conch Cement (HKEX, HKD): plus 2.97 percent, P/E 15.66, market capitalization HKD 88.2 billion

Price position and next checkpoint

Sinopharm's valuation remains below the peer multiples shown above, while its share price is still closer to the 52-week low than to the high. The November 2, 2026 earnings release is the next dated checkpoint for revenue, profit and cash-flow trends.

The closing HKEX price was HKD 15.72 on October 16, 2026 at 4:08 p.m. HKST, with the stock 0.45 percent higher on the day.